 |
|
Influence of Resection Margins and Treatment on Survival in Patients With Pancreatic Cancer—Invited Critique
Charles D. Mabry, MD
Arch Surg. 2008;143(1):83.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Cancer of the pancreas is no disease for wimps. Carcinoma of the pancreas is increasing in incidence and ranks as the fourth leading cancer death in the United States. Indeed, this is one of the more deadly diseases, as can be seen by the close similarity of incidence and death statistics for the disease: in the United States in 2006 there were 33 730 new cases of the disease and 32 300 deaths.1
The article by Butturini et al details the interaction of postoperative adjuvant therapy on survival in 875 patients with pancreatic cancer at various TNM stages. Patients were found to have either no disease (R0) or microscopic residual disease (R1) at the resection margin. This is a follow-up statistical analysis of a meta-analysis from 4 major study groups2 and was organized to decide whether R1 patients should be included in a subgroup of R0 patients or . . . [Full Text of this Article]
AUTHOR INFORMATION
RELATED ARTICLE
Influence of Resection Margins and Treatment on Survival in Patients With Pancreatic Cancer: Meta-analysis of Randomized Controlled Trials
Giovanni Butturini, Deborah D. Stocken, Moritz N. Wente, Hans Jeekel, Johaness H. G. Klinkenbijl, Kåre E. Bakkevold, Tadahiro Takada, Hirano Amano, Christos Dervenis, Claudio Bassi, Markus W. Büchler, John P. Neoptolemos, and for the Pancreatic Cancer Meta-analysis Group
Arch Surg. 2008;143(1):75-83.
ABSTRACT
| FULL TEXT
|
